Nine-week trastuzumab treatment versus 52-week trastuzumab treatment for HER2-positive early-stage breast cancer

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 12, 2012, Pages 2145-2151

  Tonyali, Onder ^a   Coskun, Ugur ^a   Sener, Nur ^b   Inanc, Mevlude ^c   Akman, Tulay ^d   Oksuzoglu, Berna ^e   Ozdemir, Nuriye Yildirim ^f   Yazilitas, Dogan ^g   Benekli, Mustafa ^a   Uner, Aytug ^a   Yamac, Deniz ^a   Demirci, Umut ^h   Yildiz, Ramazan ^b   Karaca, Halit ^c   Unal, Olcun Umit ^d   Bal, Oznur ^e   Gumus, Mahmut ^b   Buyukberber, Suleyman ^a  

^a GAZI UNIVERSITY   (Turkey)

^b DR LUTFI KIRDAR KARTAL EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^c ERCIYES UNIVERSITY   (Turkey)

^d DOKUZ EYLUL UNIVERSITY   (Turkey)

^e ANKARA ONCOLOGY EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^f ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^g Department of Medical Oncology   (Turkey)

^h ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Adjuvant therapy; Breast cancer; HER2; Trastuzumab

Indexed keywords

TRASTUZUMAB;

ADULT; AGED; ALLERGIC REACTION; ARTICLE; BREAST CANCER; CARDIOTOXICITY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG SAFETY; EARLY CANCER; FEMALE; HEART EJECTION FRACTION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MEDICAL RECORD; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM STAGING; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84871297812     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-012-1296-x     Document Type: Article

References (21)

1. Boekhout AH, Beijnen JH, Schellens JH (2011) Trastuzumab. Oncologist 16:800-810
2. Chen T, Xu T, Li Y, Liang C, Chen J, Lu Y, Wu Z, Wu S (2006) Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis. Cancer Treat Rev 37:312-320
3. Common Terminology Criteria for Adverse Events v3.0 (CTCAE) (2006) Publish Date: August 9, 2006. www.eortc.be/services/ doc/ctc/ctcaev3.pdf. Accessed 2011 July 29
4. Costa RB, Kurra G, Greenberg L, Geyer CE (2010) Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. Ann Oncol 21:2153-2160
5. Ewer MS, Lippman SM (2005) Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 23:2900-2902
6. Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, Untch M, Smith I, Baselga J, Jackisch C, Cameron D, Mano M, Pedrini JL, Veronesi A, Mendiola C, Pluzanska A, Semiglazov V, Vrdoljak E, Eckart MJ, Shen Z, Skiadopoulos G, Procter M, Pritchard KI, Piccart-Gebhart MJ, Bell R (2011) Herceptin Adjuvant (HERA) Trial Study Team Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 12:236-244
7. Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, Cardoso F, Peintinger F, Hanrahan EO, Sahin A, Guray M, Larsimont D, Feoli F, Stranzl H, Buchholz TA, Valero V, Theriault R, Piccart-Gebhart M, Ravdin PM, Berry DA, Hortobagyi GN (2009) High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 27:5700-5706
8. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkiö S, Flander M, Helle L, Ingalsuo S, Johansson K, Jääskeläinen AS, Pajunen M, Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I, Isola J, FinHer Study Investigators (2006) Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809-820
9. Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, Utriainen T, Turpeenniemi-Hujanen T, Jyrkkiö S, Möykkynen K, Helle L, Ingalsuo S, Pajunen M, Huusko M, Salminen T, Auvinen P, Leinonen H, Leinonen M, Isola J, Kellokumpu-Lehtinen PL (2009) Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol 27:5685-5692
10. McArthur HL, Mahoney KM, Morris PG, Patil S, Jacks LM, Howard J, Norton L, Hudis CA (2011) Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer. Cancer 117:5461-5468
11. Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, Schlessinger J, Lippman ME, King CR (1990) Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 8:103-112
12. Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE Jr, Martino S, Mamounas EP, Kaufman PA, Wolmark N (2011a) Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 29:3366-3373
13. Perez EA, Suman VJ, Davidson NE, Gralow JR, Kaufman PA, Visscher DW, Chen B, Ingle JN, Dakhil SR, Zujewski J, Moreno-Aspitia A, Pisansky TM, Jenkins RB (2011b) Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol 29:4491-4497
14. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, La'ng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672
15. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2- positive breast cancer. N Engl J Med 353:1673-1684
16. Sawaki M, Tokudome N, Mizuno T, Nakayama T, Taira N, Bando H, Murakami S, Yamamoto Y, Kashiwaba M, Iwata H, Uemura Y, Ohashi Y (2011) Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients: randomized controlled trial [RESPECT (N-SAS BC07)]. Jpn J Clin Oncol 41:709-712
17. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182
18. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712
19. Slamon D, Eiermann W, Robert N (2005) Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC/T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC/TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER-2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 94(Suppl 1):S5a
20. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J (2011) Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273-1283
21. Spielmann M, Roché H, Delozier T, Canon JL, Romieu G, Bourgeois H, Extra JM, Serin D, Kerbrat P, Machiels JP, Lortholary A, Orfeuvre H, Campone M, Hardy-Bessard AC, Coudert B, Maerevoet M, Piot G, Kramar A, Martin AL, Penault-Llorca F (2009) Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 27:6129-6134